Martin Harutyunyan, Director of OncoDaily LA, shared MASCC’s post on LinkedIn, adding:
“As announced earlier, The Multinational Association of Supportive Care in Cancer (MASCC) has launched the Supportive CARE DIGEST, a new series highlighting important developments in supportive cancer care.
Here is my first video in the series. Looking forward to your questions, discussions, and any recommendations for future topics.”
Quoting MASCC’s post:
“Our first episode of the Supportive CARE DIGEST is now available.
Dr. Martin Harutyunyan reviews the New England Journal of Medicine Phase 2 trial of ponsegromab, a GDF‑15–neutralizing antibody showing promising results in cancer cachexia. The study reported improvements in weight, appetite, anorexia symptoms, physical activity, and skeletal muscle, along with a favorable safety profile.
Watch the episode and stay connected with MASCC for updates in supportive cancer care.”
Other articles featuring Martin Harutyunyan and MASCC on OncoDaily.